Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era.
COVID-19
hematology
immunotherapy
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
27 10 2022
27 10 2022
Historique:
received:
02
09
2022
revised:
19
10
2022
accepted:
20
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
Patients with hematological malignancies are at greater risk of severe COVID-19 and have been prioritized for COVID-19 vaccination. A significant proportion of them have an impaired vaccine response, both due to the underlying disease and to the treatments. We conducted a prospective observational study to identify the specific risks of the outpatient population with hematological diseases. Between 22 December 2021 to 12 February 2022, we followed 338 patients of which 16.9% ( In the immunocompromised population of patients with hematological malignancies, the underlying treatment of blood cancer by immunotherapy appears to be a risk factor for SARS-CoV-2 infection and for developing a severe form.
Sections du résumé
BACKGROUND
Patients with hematological malignancies are at greater risk of severe COVID-19 and have been prioritized for COVID-19 vaccination. A significant proportion of them have an impaired vaccine response, both due to the underlying disease and to the treatments.
METHODS
We conducted a prospective observational study to identify the specific risks of the outpatient population with hematological diseases.
RESULT
Between 22 December 2021 to 12 February 2022, we followed 338 patients of which 16.9% (
CONCLUSION
In the immunocompromised population of patients with hematological malignancies, the underlying treatment of blood cancer by immunotherapy appears to be a risk factor for SARS-CoV-2 infection and for developing a severe form.
Identifiants
pubmed: 36366475
pii: v14112377
doi: 10.3390/v14112377
pmc: PMC9696091
pii:
doi:
Substances chimiques
tixagevimab
0
cilgavimab
1KUR4BN70F
COVID-19 Vaccines
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Clin Microbiol Infect. 2022 Aug;28(8):1057-1065
pubmed: 35289294
Ann Rheum Dis. 2021 Oct;80(10):1330-1338
pubmed: 34127481
Transplantation. 2022 Jul 1;106(7):1421-1429
pubmed: 35283457
Lancet Glob Health. 2022 Mar;10(3):e326-e328
pubmed: 35180408
Lancet. 2022 Mar 5;399(10328):905-907
pubmed: 35090602
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Nat Med. 2022 Jun;28(6):1297-1302
pubmed: 35322239
Ann Rheum Dis. 2022 May;81(5):720-728
pubmed: 35022159
Lancet Respir Med. 2021 Mar;9(3):251-259
pubmed: 33341155
Nat Commun. 2022 Feb 14;13(1):864
pubmed: 35165284
Lancet Rheumatol. 2021 Jun;3(6):e419-e426
pubmed: 33786454
Clin Microbiol Infect. 2022 Jun;28(6):885.e7-885.e11
pubmed: 35259530
Int J Infect Dis. 2022 Mar;116:38-42
pubmed: 34971823
Br J Haematol. 2021 Mar;192(5):e121-e124
pubmed: 33522598
Blood. 2022 Aug 4;140(5):445-450
pubmed: 35588468
N Engl J Med. 2021 Sep 23;385(13):1184-1195
pubmed: 34347950
EClinicalMedicine. 2020 Oct;27:100549
pubmed: 33073216
Am J Hematol. 2021 Aug 1;96(8):934-944
pubmed: 33909916
N Engl J Med. 2022 Apr 7;386(14):1314-1326
pubmed: 35196424
N Engl J Med. 2022 Jun 9;386(23):2188-2200
pubmed: 35443106
J Infect. 2021 Mar;82(3):329-338
pubmed: 33549624
Blood. 2022 Feb 10;139(6):942-946
pubmed: 34905598
Blood. 2022 Mar 10;139(10):1588-1592
pubmed: 34748627